FIG. 2.

IVT administration of ADVM-022 provides levels of intraocular aflibercept expression comparable with those measured 21–32 days following IVT injection of aflibercept recombinant protein (n = 4 eyes, 2 animals for each data point) (A) Vitreous humor. (B) Aqueous humor. (C) Retina. (D) Choroid. The dotted lines indicate the times on the decay curves when recombinant aflibercept levels are equivalent to those seen in the ADVM-022-treated groups' low (2 × 10¹¹ vg/eye, purple), middle (6 × 10¹¹ vg/eye, green), and high (2 × 10¹² vg/eye, red) doses tested on day 56. Error bars represent standard deviations. Printed with permission from Kiss et al.¹⁴ IVT, intravitreal.